Infectious Diseases and Global Health

Basic definition of infection refers to the harm caused by a foreign particle entering the host body. Some are mild and few are life-threatening depending on the type of organism causing it. Starting from the cause, symptoms, detecting the organism, clinical studies, treatment, controlling it before spreading, preventing the infection, developing new methods and techniques for diagnosis to developing new drugs and treatment strategies, you can discuss at our Euro Infectious Diseases 2020 The global market for infectious disease treatments is a result of the growth in demand for new pharmaceutical treatments, vaccines development, and environmental products. In 2017, the global market for the treatment of infectious disease totaled $64.8 billion. The market should total $99 billion by 2022, growing at a CAGR of 8.9% from 2017 to 2022.

Market Analysis:The infectious diseases and global health market is a dynamic and expanding sector, primarily driven by the rising prevalence of infectious diseases, increasing antimicrobial resistance, and significant technological advancements. The market is broadly segmented into therapeutics (drugs and vaccines) and diagnostics. The therapeutics market, valued at around $124 billion to $243 billion, is dominated by viral infections and is projected to grow steadily, with North America holding the largest share due to its robust healthcare infrastructure and high R&D investment. Simultaneously, the infectious disease diagnostics market, valued at approximately $25 billion, is also seeing robust growth driven by the demand for rapid and accurate testing, particularly at the point of care. The overall market is shaped by global health priorities, including pandemic preparedness, and is increasingly leveraging digital health technologies like telemedicine and AI to improve disease surveillance, diagnosis, and patient care, with the global digital health market alone projected to reach over $1.5 trillion by 2032. For more details:

Scope & Importance

The infectious diseases and antimicrobial resistance (AMR) market is growing as drug-resistant infections rise worldwide. The antibiotic resistance segment is valued at USD 9.3 billion in 2025 and projected to reach USD 12.1 billion by 2030 (CAGR 5.5%). Growth is fueled by increasing cases, public–private funding, and regulatory support. Asia-Pacific leads the market, South America shows the fastest growth, and pneumonia remains the largest disease segment.

The AMR diagnostics market, worth USD 4.6 billion in 2024, is expected to hit USD 6.7 billion by 2030 (CAGR 6.6%). Demand is rising for rapid, point-of-care tests, especially PCR-based technologies. North America currently dominates, but India and other emerging economies are expanding quickly, driven by the need for early detection and better antibiotic stewardship.

The AMR surveillance market is valued at USD 6.24 billion in 2025 and forecasted to reach USD 8.23 billion by 2030 (CAGR 5.7%). Growth is driven by molecular diagnostics, AI-powered analytics, and government programs. North America holds the largest share, while Asia-Pacific is the fastest-growing region. Hospitals remain the main users, with diagnostic labs gaining momentum.

Target Audience:

valued at USD 3.5–4 billion in 2025, and expected to grow at a CAGR of 5% due to rising resistance in pathogens such as E. coli, Klebsiella pneumoniae, and Pseudomonas aeruginosa. Federal funding has increased, with initiatives like CARB-X awarding over USD 360 million to early-stage AMR projects and BARDA investing more than USD 1 billion in advanced-stage antibiotic and diagnostic development. Rapid diagnostic tests for AMR are also gaining traction, with adoption projected to grow 2x by 2030.

Looking ahead, the U.S. infectious diseases and AMR market is poised for steady expansion, projected to reach USD 33–35 billion by 2030. Government incentives such as the FDA’s QIDP designation, which provides market exclusivity and priority review for new antibiotics, are encouraging innovation. However, the market faces hurdles: the average cost of antibiotic R&D exceeds USD 1.5 billion, while uptake remains slow due to stewardship programs and reimbursement challenges. Despite these barriers, strong federal support and industry investment position the U.S. as a global leader in infectious disease management, with increasing focus on next-generation antibiotics, vaccines, and precision diagnostics to combat AMR.

Market access is also moving: Europe has approved new agents (e.g., Emblaveo and Exblifep) for difficult Gram-negative infections, expanding the treatable addressable market while emphasizing antimicrobial stewardship frameworks at launch. Meanwhile, lawmakers debate transferable exclusivity vouchers (TEVs) as a pull incentive—industry sees them as catalytic, while public-health groups raise affordability and spillover concerns. Whichever design prevails, a predictable EU pull-incentive is the swing factor for late-stage pipeline investment and partnering decisions through 2030.

Infectious Diseases and Antimicrobial Resistance in Asia:

Universities and Research Institutes:

USA

Antimicrobial Conferences /

Clinical Microbiology Conferences /

EUROPE

Antimicrobial Conferences /

Clinical Microbiology Conferences /

Workshops

Workshops are typically interactive and hands-on sessions that allow attendees to learn practical skills or techniques, explore specific topics in more depth, and engage in discussions with other participants and experts in the field.

Workshops can provide attendees with opportunities to learn new techniques, approaches, and methodologies that they can apply to their work or research.

Workshops offer a platform for attendees to connect with other participants who share similar interests and expertise. They can exchange ideas, establish new collaborations, and build relationships that can lead to future opportunities.

Workshops can attract a diverse range of attendees, including students, researchers, industry professionals, and policymakers.

Workshop & Presentation

The main aim behind the inclusion of workshops is to facilitate the transfer of knowledge through audience interactions. Workshops can be 3 to 6 hours in length, depending on the subject matter and relevance of the topics discussed. Organizers should select the workshop type and their preferred duration, in the workshop proposal. The following are the available possible workshop types: Regular workshop: 1 to 3 hours sessions with up to 5 presentations. Such workshops allow ample time for audience interactions. Skills building workshop: 3 to 6 hours sessions, organized to specifically build the capacity and knowledge of conference delegates. These workshops include only 1-3 presentations and focus a majority of their time on collaborative learning and skill development. Usually workshops would be panned with a number of presentations that will be followed by a discussion. The maximum limit of abstract submissions allowed for this type is 5. Workshops that combine 1-2 presentations with a panel discussion are still considered to be regular workshops. In these cases, we urge you to add the number of abstracts, and include the names and affiliations of the panellists.

e information such as - the value of the workshop, coherence between the presentation and related topic of the workshop, etc. Additionally, describe the format of your workshop in this section. The maximum number of words is 250.
2. Aim: Summarise the impact of the proposed workshop in a short messages of a maximum of 150 words. Presentations: Select the number of presentations in this section. The maximum number of presentations for any workshop is 5 presentations.
3. Presenters: Select the number of presenters in this section. The presenters name, institute, and email address should be entered.
4. Social Media Statement: Provide us with a statement about your workshop using up to 120 characters that can be used for promotions on our various social media platforms. Be sure to use words or phrases that will capture attention and create a call to action, and include relevant hashtags.

Hotel & Travel

Hotel address & name

Sheraton Heathrow Hotel Colnbrook By Pass, Harmondsworth, West Drayton, Middlesex, UB7 0HJ, United Kingdom

About City

London holds status of the world's most powerful, most coveted, most influential, most visited, most expensive, most sustainable, most investment-friendly, and most popular-for-work city. Arts, commerce, education, entertainment, fashion, finance, healthcare, journalism, professional services, research and development, tourism, and transportation are all affected. In terms of economic performance, London is ranked 26th out of 300 big cities. It is one of the world's most important financial centres, with the fifth- or sixth-largest metropolitan area GDP. It is the most visited city in terms of international arrivals, and its airport system is the busiest in terms of passenger flow. It is the most popular investment location, with the most international shops of any city. After Paris, London has the second-highest number of ultra-wealthy persons in Europe in 2017.

Buckingham Palace is the official London residence of the British monarch, famous for its grand facade and the spectacular "Changing of the Guard" ceremony, a highly popular attraction where visitors can witness the precision and pageantry of the Queen's Guard.

Tower of London is a historic castle on the River Thames with nearly a millennium of history, serving as a fortress, a royal palace, and a prison. Highlights include the magnificent Crown Jewels, protected by the Beefeaters, and the resident ravens, which are said to ensure the kingdom's prosperity.

Shopping Paradise Shopaholics rejoice in Singapore's myriad shopping destinations, from luxury boutiques along Orchard Road to eclectic markets like Bugis Street. Whether you seek designer labels or unique souvenirs, Singapore offers something for every shopper.

are the heart of British political life. This site is celebrated for its stunning Gothic Revival architecture and the iconic chimes of the clock, which have become a symbol of London itself.

Safe and Efficient London is widely regarded as a safe and highly efficient city, though like any major urban center, some areas are safer than others. The City of London, for instance, is noted for its low crime rate, and many residential neighborhoods maintain a high level of security. The city's efficiency is most evident in its comprehensive public transportation system, which is overseen by Transport for London (TfL) and includes the world-famous Underground, an extensive bus network, and various rail services. This integrated system, while sometimes crowded and expensive, allows for seamless travel throughout the capital, making it a critical part of London's infrastructure and a key to its smooth functioning.

Clinicians & Infectious Disease Specialists 20%

Microbiologists & Virologists 15%

Pharmaceutical Researchers 10%

Healthcare Professionals 15%

Bacteriologists & Parasitologists 20%

Public Health Professionals & Faculty and Scientists 7%

Pathologists & Epidemiologists 5%

Biotechnology Companies & Drug Manufacturing Companies 8%

Therapeutic vaccination against HPV-related tumors: Study shows nanoparticles make difference

Researchers from the German Cancer Research Center (DKFZ) have collaborated with the SILVACX project...

Transparent hydrogen boride nanosheets show antimicrobial properties against multiple pathogens

The global fight against infectious diseases faces two major challenges:

Therapeutic vaccination against HPV-related tumors: Study shows nanoparticles make difference

Researchers from the German Cancer Research Center (DKFZ) have collaborated with the SILVACX project group at Heidelberg University to develop a therapeutic vaccination concept that can mobilize the immune system to target cancer cells. The team showed that virus peptides coupled to silica nanoparticles can elicit effective T-cell responses against HPV-related tumors. In a mouse model, the nanoparticle-based vaccine was able to partially or completely suppress HPV-related tumors. of cancer. Preventive HPV vaccinations ward off infection with the pathogens and can thus prevent the development of cancer. However, there are currently no therapeutic vaccines that combat existing precancerous lesions or tumors. A new vaccination method developed by a research team led by Angelika Riemer from the DKFZ and the SILVACX project group based at Heidelberg University relies on silica nanoparticles. This stable material, also known as silicon dioxide or silicic acid, has already proven itself in various medical applications. The silica particles are first coated to make them biocompatible. They are then loaded with short fragments of the viral proteins present in the cancer cells. To this end, the researchers select protein segments that are known to activate the human immune system. After injection, specialized immune cells—known as antigen-presenting cells—take up the particles and present the viral epitopes on their surface. This activates cytotoxic T cells, which specifically recognize and destroy cancer cells. The combination with an additional adjuvant was particularly effective. The researchers used mice whose immune systems had been “humanized,” meaning they can present the same epitopes as humans. In these animals, the vaccination led to a significant activation of cytotoxic T cells. In some of the mice, existing HPV-positive tumors were completely suppressed, and these mice survived longer. “These are encouraging results that confirm our decision to continue developing the nanoparticle vaccine system. It is versatile and could be used in the future not only against HPV-associated cancers, but also against other tumors or infectious diseases,” explains study leader Riemer. Silica nanoparticles are the core element of the therapeutic vaccination process. They protect the vaccine epitopes in the body from rapid degradation, thus ensuring their bioavailability and uptake and presentation by immune cells. They are also characterized by their stability and ease of manufacture. Vaccines based on silica nanoparticles could therefore also be used in regions where it is difficult to maintain the refrigeration chain required for most vaccines—an important advantage for global application.

Transparent hydrogen boride nanosheets show antimicrobial properties against multiple pathogens

The global fight against infectious diseases faces two major challenges: the threat of new pandemic outbreaks and the alarming rise of antimicrobial resistance driven by the excessive use of antibiotics. As pathogens continue to evolve and spread, researchers are urgently seeking innovative technologies that can effectively combat viruses, bacteria, and fungi conveniently in everyday settings. represent an exciting new frontier. Initially explored for potential applications in electronics, energy storage, and catalysis, the interactions between HB nanosheets and biomolecules have remained largely unexplored—until now. In a recent study, a research team involving Professor Masahiro Miyauchi and Associate Professor Akira Yamaguchi from the Department of Materials Science and Engineering at Institute of Science Tokyo, Japan, together with graduate student Andi Mauliana, Professor Takahiro Kondo from the Institute of Pure and Applied Sciences at the University of Tsukuba, Professor Takeshi Fujita from the School of Engineering at the Kochi University of Technology, researchers Dr. Kayano Sunada, Dr. Keiichi Kobayashi, Dr. Takeshi Nagai, and Dr. Hitoshi Ishiguro from Kanagawa Institute of Industrial Science and Technology, has discovered that HB nanosheets exhibit excellent antibacterial, antiviral, and antifungal properties. The researchers first fabricated transparent films by coating glass substrates with a dispersed solution of HB nanosheets. They then tested these films against a wide variety of microorganisms. The coated surfaces exhibited exceptional antimicrobial performance, inactivating the SARS-CoV-2, influenza, and feline caliciviruses down to detection limits within just 10 minutes at room temperature—without the need for light activation. Similar effects were observed against various bacteriophages, and multiple types of bacteria, such as Escherichia coli and Staphylococcus aureus, and fungi, such as Aspergillus niger and Penicillium pinophilum. The ability of HB nanosheets to inactivate these bacteria and fungi to the detection limit confirms the effectiveness of this material in combating a variety of microbial agents. The team then investigated the underlying mechanisms behind this broad-spectrum antimicrobial activity, revealing that it originates from the nanosheets’ ability to denature microbial proteins through strong physicochemical interactions. What makes these findings particularly exciting is the versatility of HB nanosheets as transparent coating materials. Unlike metal-based antimicrobials, which may leach or lack transparency, and photocatalyst-based coatings that require ultraviolet light activation, HB nanosheets function effectively in darkness and maintain optical clarity. Laboratory tests further demonstrated their effectiveness under dry conditions, mimicking real-world scenarios where pathogens might be transferred by coughing or sneezing onto everyday surfaces. Amid concerns of another pandemic like the COVID-19 outbreak, HB nanosheets can be applied as transparent coatings for items and textiles to reduce infection risks. Additionally, due to their antifungal properties, they could also be used on various materials to help maintain cleanliness in everyday surroundings.

Molecule can disarm pathogenic bacteria without harming beneficial microbes

A consortium of researchers with multidisciplinary skills, coordinated by INRAE and including the CNRS, the Université Paris-Saclay and Inserm, has identified a molecule capable of “disarming” pathogenic bacteria in the face of the immune system, without any negative effects on the host microbiota, promising a new strategy to combat antibiotic resistance. WHO, 5 million people die every year worldwide as a result of antibiotic resistance. This could become the leading cause of death by 2050. Although antibiotics have considerably reduced the mortality associated with infectious diseases, their sometimes excessive and abusive use has led to the development of bacterial resistance. Furthermore, as antibiotics generally target pathways essential for bacterial survival, they have a broad spectrum of action but lack specificity, with repercussions on all the bacteria of the host microbiota. The identification and characterization of new bacterial drug targets and the design of innovative anti-infectives is therefore a scientific and medical priority. An INRAE research team has identified the mutation frequency decline (Mfd) protein, a virulence factor produced by all bacteria and essential for them to resist the host immune system. This protein has the additional function of promoting spontaneous and random mutations, which increase the capacity of bacteria to develop resistance. Disarming the invading bacteria and protecting the microbiota Following this discovery, a consortium of researchers with multidisciplinary skills, coordinated by INRAE and including the CNRS, the Université Paris-Saclay and Inserm, came together to identify and develop a compound capable of blocking this protein and thus “disarming” the pathogenic bacteria. From a library of 5 million molecules, the scientists identified a promising molecule, named NM102, capable of binding to the Mfd protein and preventing its activation. They carried out a series of tests, in vitro and then in vivo in insect and mouse models, which revealed three major effects of this molecule: It does not kill bacteria in the absence of toxic compounds produced by the immune system. It reduces the quantity of pathogenic bacteria in infected organs, without damaging the host microbiota. It is capable of blocking the function of Mfd as a mutation factor, thereby reducing the bacteria’s ability to develop resistance to antimicrobials. The molecule is thus capable of “disarming” pathogenic bacteria while protecting the bacteria in the microbiota. Most promisingly, this molecule is also effective against bacterial strains that are resistant to current treatments and originate from hospital patients.